Cardiovascular Disease (CVD)

ANCA-Associated Vasculitis Associated With Cardiovascular Events

Publish Date December 21, 2021

Researchers studied the association between ANCA-associated vasculitis and adverse cardiovascular outcomes.

Midlife CV Conditions, Risk Factors Linked to Cognitive Decline

Publish Date January 25, 2022

Most cardiovascular conditions more strongly linked to cognition among women

Diabetic Kidney Disease Without Albuminuria Ups CKD Progression Risk

Publish Date January 14, 2022

A study of Chinese patients revealed that the increased risk of chronic kidney disease progression was present regardless of baseline kidney function.

Exposure to Nonessential Metals Linked to Risk for Atherosclerosis

Publish Date January 12, 2022

Odds ratios increased for subclinical atherosclerosis presence in at least one territory for arsenic, cadmium, titanium

ACC/AHA: Base Coronary Revascularization on Clinical Indications

Publish Date January 10, 2022

Treatment decisions for patients with coronary artery disease should be based on clinical indications, regardless of sex, race, ethnicity

Leqvio Approved as Twice-Yearly Injection to Lower LDL-C in High-Risk Patients

Publish Date January 7, 2022

The approval was based on data from the ORION-9, ORION-10, and ORION-11 trials that evaluated Leqvio in patients 18 years of age and older with HeFH or clinical ASCVD.

More Physical Activity Is Better for Patients With CVD

Publish Date January 6, 2022

Benefit of physical activity with regard to health outcomes appears to be influenced by cardiovascular health status

Substituting Brand-Name With Generic Heart Meds Yields Savings

Publish Date January 4, 2022

Generic substitutions for brand-name medications could save $641 million per year, including $135 million paid by patients

High Leptin Increases Mortality Risk in Stable Coronary Heart Disease

Publish Date December 30, 2021

Researchers at AHA 2021 presented a study that sought to determine whether high leptin affects the risk for mortality or morbidity in patients with stable CHD.

Early Treatment With Sotrovimab Decreases Risk for Progression to Severe COVID-19

Publish Date December 29, 2021

Researchers conducted a study to determine whether treatment with sotrovimab decreases the risk for severe disease progression among high-risk patients with mild-to-moderate COVID-19.